Mounjaro is not a semaglutide. Mounjaro’s active ingredient is tirzepatide, a different molecule that works on two gut hormone receptors instead of one. Semaglutide is the active ingredient in Ozempic and Wegovy. The confusion is understandable because both drugs are weekly injections used for type 2 diabetes and weight loss, but they belong to different drug classes and work in distinct ways.
How Mounjaro Differs From Semaglutide
Semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) activates a single receptor in your body: the GLP-1 receptor. GLP-1 is a hormone your gut releases after eating that signals your pancreas to produce insulin, slows digestion, and reduces appetite.
Tirzepatide, the drug in Mounjaro, activates two receptors: the same GLP-1 receptor plus a second one called the GIP receptor. GIP is another gut hormone involved in insulin release and fat metabolism. This dual action is why tirzepatide is sometimes called a “dual incretin agonist” or “twincretin.” It mimics two natural hormones at once rather than just one.
Interestingly, tirzepatide doesn’t hit both receptors equally. Its structure closely resembles native GIP, so it activates the GIP receptor at full strength. Its effect on the GLP-1 receptor is about fivefold weaker than GLP-1 itself, but it compensates by causing less receptor burnout over time. That means the GLP-1 receptor stays responsive longer, which may partly explain why tirzepatide outperforms semaglutide in clinical trials despite having weaker GLP-1 binding.
Head-to-Head Results
The SURPASS-2 trial directly compared Mounjaro against Ozempic (semaglutide 1 mg) in nearly 1,900 adults with type 2 diabetes over 40 weeks. All three doses of tirzepatide beat semaglutide on both blood sugar control and weight loss.
For A1C reduction (a measure of average blood sugar over three months), semaglutide lowered levels by 1.86 percentage points. Tirzepatide lowered them by 2.09 points at the 5 mg dose, 2.37 points at 10 mg, and 2.46 points at 15 mg.
Weight loss showed an even bigger gap. Patients on semaglutide lost an average of 6.2 kg (about 6.7% of body weight). Tirzepatide patients lost 7.8 kg at the lowest dose, 10.3 kg at the middle dose, and 12.4 kg (13.1% of body weight) at the highest dose. That means the top tirzepatide dose roughly doubled the weight loss seen with semaglutide.
Brand Names and Approved Uses
The brand names can add to the confusion, so here’s how they break down:
- Tirzepatide is sold as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management).
- Semaglutide is sold as Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management).
Each molecule has two brand names because the FDA approved them separately for different conditions. Mounjaro was approved first for type 2 diabetes, and Zepbound followed in November 2023 specifically for weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like high blood pressure or high cholesterol.
Dosing Comparison
Both medications are once-weekly injections given under the skin, typically in the abdomen, thigh, or upper arm. The dosing schedules differ in their ranges.
Mounjaro starts at 2.5 mg weekly for the first four weeks, then increases to 5 mg. From there, your doctor can raise the dose in increments every four weeks up to a maximum of 15 mg per week. Ozempic starts lower at 0.25 mg weekly, steps up to 0.5 mg after four weeks, and can be gradually increased to a maximum of 2 mg per week. The numbers aren’t directly comparable since the two molecules have different potencies, but both follow a similar strategy of starting low and increasing slowly to reduce side effects.
Side Effects Are Similar
Because both drugs act on the GLP-1 receptor, they share a common set of gastrointestinal side effects. Nausea, vomiting, diarrhea, and decreased appetite are the most frequently reported issues with both tirzepatide and semaglutide. These tend to be worst during the first few weeks and after each dose increase, then gradually improve as your body adjusts.
The slow dose escalation for both drugs exists specifically to minimize these effects. Skipping ahead to higher doses without titrating up increases the likelihood of significant nausea. Most people find the side effects manageable, but they’re a common reason some patients stay at a lower dose rather than pushing to the maximum.
Why People Confuse Them
Mounjaro and Ozempic launched around the same time, treat overlapping conditions, look similar (both are pen injectors), and follow the same weekly schedule. Social media and news coverage often lump them together under the umbrella of “GLP-1 drugs,” which is technically inaccurate for Mounjaro since it’s a dual-receptor drug. The word “semaglutide” has also become a catch-all term in casual conversation for any injectable weight loss or diabetes medication, even though it refers to one specific molecule.
If your prescription says Mounjaro or Zepbound, you’re taking tirzepatide. If it says Ozempic or Wegovy, you’re taking semaglutide. They are not interchangeable, and switching between them requires a new prescription and a separate dose titration.